Grace Therapeutics, Inc. Common Stock
Veridion Score
Composite trend over time
Why is GRCE moving today?
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for GRCE.
GRCE insider activity
Grace Therapeutics, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for GRCE.
GRCE contract awards, year to date.
Public federal awards linked to this ticker.
GRCE lobbying filings, year to date.
Registered lobbying filings matched to Grace Therapeutics, Inc. Common Stock.